Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued AFFITOPE AD02 vaccination extension study in prior AFF006 participants with Alzheimer's disease
2012-005280-27Phase 2Terminated
- Sponsor
- AFFiRiS
- Start
- Dec 2012
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Continued AFFITOPE AD02 vaccination with Control or prior placebo comparator group (2 arms). Primary endpoint: Withdrawal criteria. Started Dec 2012; status: terminated.
02
Drugs
affitope ad02
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2012-005280-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005280-27.